Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients

(2019) Aleksandra Markiewicz et al.   Cancers

Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene

(2019) Suvimol Niyomnaitham et al.   PeerJ

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

(2019) Lei Zhang et al.   Molecular Cancer

The crucial role of ZEB2: From development to epithelial-to-mesenchymal transition and cancer complexity

(2019) Masoumeh Fardi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

(2018) Elham Azizi et al.   CELL

Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing

(2018) Anna K. Casasent et al.   CELL

Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer

(2018) Peter J. Chockley et al.   JOURNAL OF CLINICAL INVESTIGATION

Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process

(2018) Fang Li et al.   ONCOLOGY REPORTS

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)

(2018) Young Kwang Chae et al.   Scientific Reports

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

(2018) A. Asgarova et al.   OncoImmunology

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion

(2018) Peixin Dong et al.   Frontiers in Oncology

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8 + T and NK cell-mediated antitumor responses

(2017) Zhenhua Zhang et al.   MOLECULAR IMMUNOLOGY

New insights into the role of EMT in tumor immune escape

(2017) Stéphane Terry et al.   Molecular Oncology

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

(2017) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repurposing Antiestrogens for Tumor Immunotherapy

(2017) Thomas Welte et al.   Cancer Discovery

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis

(2017) Minghui Zhang et al.   Oncotarget

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

(2017) C. Allison Stewart et al.   Oncotarget

Macrophages promote the progression of premalignant mammary lesions to invasive cancer

(2017) Emily C. Carron et al.   Oncotarget

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer

(2017) Sushil Kumar et al.   OncoImmunology

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

(2016) Y. Lou et al.   CLINICAL CANCER RESEARCH

Targeting the programmed cell death-1 pathway in breast and ovarian cancer

(2016) Leisha A. Emens et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

(2016) Sehui Kim et al.   HUMAN PATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment

(2016) Jaehong Kim et al.   MEDIATORS OF INFLAMMATION

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

(2016) Thomas Welte et al.   NATURE CELL BIOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells

(2016) Nikolaos Svoronos et al.   Cancer Discovery

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes

(2016) A. Forero et al.   Cancer Immunology Research

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

(2016) Christin Ungewiss et al.   Scientific Reports

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

(2015) M. P. Mak et al.   CLINICAL CANCER RESEARCH

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

(2015) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

(2015) Razvan Cristescu et al.   NATURE MEDICINE

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

(2014) Chunxiao Xu et al.   CANCER CELL

Acetylation of Snail Modulates the Cytokinome of Cancer Cells to Enhance the Recruitment of Macrophages

(2014) Dennis Shin-Shian Hsu et al.   CANCER CELL

Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

(2014) M. D. Iglesia et al.   CLINICAL CANCER RESEARCH

Tumor Plasticity Interferes with Anti-Tumor Immunity

(2014) Salem Chouaib et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Targeting CD8+ T-cell tolerance for cancer immunotherapy

(2014) Stephanie R Jackson et al.   Immunotherapy

TGFβ: A player on multiple fronts in the tumor microenvironment

(2014) Fabian Caja et al.   Journal of Immunotoxicology

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

A New Strategy Using ALDHhigh-CD8+T Cells to Inhibit Tumorigenesis

(2014) Huiyan Luo et al.   PLoS One

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis

(2013) I. Akalay et al.   CANCER RESEARCH

Twist1 Induces CCL2 and Recruits Macrophages to Promote Angiogenesis

(2013) J. M. Low-Marchelli et al.   CANCER RESEARCH

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

The Role of MicroRNAs in Breast Cancer Stem Cells

(2013) Daniela Schwarzenbacher et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

(2013) Maria Ascierto et al.   Journal of Translational Medicine

Dual role of immunomodulation by anticancer chemotherapy

(2013) Michael R Shurin   NATURE MEDICINE

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression

(2012) Young-Ho Ahn et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

(2012) Lucia Hernandez et al.   JOURNAL OF PATHOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma

(2012) Wei-Yi Cheng et al.   PLoS One

SIGNATURE: A workbench for gene expression signature analysis

(2011) Jeffrey T Chang et al.   BMC BIOINFORMATICS

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

(2011) Maria Libera Ascierto et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-Mesenchymal Transition in Cancer

(2011) M. J. Schliekelman et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

MicroRNAs as regulators of epithelial-mesenchymal transition

(2011) Philip A. Gregory et al.   CELL CYCLE

The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200–dependent pathway in mice

(2011) Yanan Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

A MicroRNA Expression Signature for Cervical Cancer Prognosis

(2010) X. Hu et al.   CANCER RESEARCH

Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non-Small Cell Lung Cancer

(2010) P. Ceppi et al.   MOLECULAR CANCER RESEARCH

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

(2010) J. H. Taube et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

(2010) Li Yang et al.   TRENDS IN IMMUNOLOGY

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

(2010) Thomas Condamine et al.   TRENDS IN IMMUNOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells

(2009) Yohei Shimono et al.   CELL

Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development

(2009) Verena Greifenberg et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

(2009) D. L. Gibbons et al.   GENES & DEVELOPMENT

Structure of Natural Killer Cell Receptor KLRG1 Bound to E-Cadherin Reveals Basis for MHC-Independent Missing Self Recognition

(2009) Yili Li et al.   IMMUNITY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

(2009) Ulrich Wellner et al.   NATURE CELL BIOLOGY

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

(2009) Pierre Farmer et al.   NATURE MEDICINE

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Double-Negative Feedback Loop between ZEB1-SIP1 and the microRNA-200 Family Regulates Epithelial-Mesenchymal Transition

(2008) C. P. Bracken et al.   CANCER RESEARCH

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

(2008) Ulrike Burk et al.   EMBO REPORTS

Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation

(2008) Milada Mahic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

(2008) S.-M. Park et al.   GENES & DEVELOPMENT

The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional RepressorsZEB1andZEB2

(2008) Manav Korpal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY